The world first breast cancer vaccine starts clinical trials in Cleveland Clinic
- Engineered Soybeans with Pig Protein: A Promising Alternative or Pandora’s Dish?
- Severe Fever with Thrombocytopenia Syndrome (SFTS): A Tick-Borne Threat with High Mortality
- Why Isolating Bananas Extends Their Shelf Life?
- This common vitamin benefits the brain and prevents cognitive decline
- New report reveals Nestlé adding sugar to infant formula sold in poor countries
- Did Cloud Seeding Unleash a Deluge in Dubai?
The world first breast cancer vaccine starts clinical trials in Cleveland Clinic
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
The world first breast cancer vaccine starts clinical trials in Cleveland Clinic
According to data released by the World Health Organization, there are as many as 2.26 million new cases of breast cancer worldwide in 2020, surpassing the 2.2 million cases of lung cancer. This also means that breast cancer has replaced lung cancer as the world’s largest cancer.
A few days ago, the Cleveland Clinic in the United States announced that it will launch a human clinical trial designed to test a vaccine that can prevent triple-negative breast cancer.
Negative breast cancer is a very aggressive and deadly breast cancer. At present, some conventional drugs are not effective for triple-negative breast cancer, and they can only be prevented and treated by mastectomy.
The triple-negative breast cancer vaccine developed by the Cleveland Clinic has achieved good results in laboratory and animal tests. With the US Food and Drug Administration (FDA) approved the vaccine’s research new drug application, it means that human trials are about to start.
The trial will include 18 to 24 patients who have been treated for early triple-negative breast cancer within the past three years without tumors. They will receive three injections, two weeks apart each time.
Researchers say that triple-negative breast cancer accounts for approximately 12% to 15% of all breast cancer patients, and nearly a quarter of patients die within five years after diagnosis. This is more common in African American women and women with BRCA1 mutations.
Although the trial will only include early triple-negative breast cancer survivors with a high risk of recurrence, the researchers hope that the next step will be to vaccinate healthy people with a high risk of the disease, such as those with a BRCA1 gene mutation.
In the long run, once the test results are better, the vaccine will become a preventive vaccine for healthy women to prevent them from developing triple-negative breast cancer.
It is understood that triple-negative breast cancer refers to breast cancer in which the results of the immunohistochemical examination of the cancer tissue are negative for estrogen receptor, progesterone receptor and the proto-oncogene Her-2. With special biological behavior and clinicopathological characteristics, the prognosis is worse than other types.
The clinical manifestation of triple-negative breast cancer is an aggressive course, with a higher risk of distant metastasis, a higher chance of visceral metastasis than bone metastasis, and a higher chance of brain metastasis. The risk of distant metastasis of triple-negative breast cancer reaches its peak at 3 years, and may decrease thereafter.
The world first breast cancer vaccine starts clinical trials in Cleveland Clinic
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
